Literature DB >> 28154087

Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.

Julia Schanda1, Chun-Wei Lee2, Katharina Wohlan2, Uta Müller-Kuller1,3, Hana Kunkel1, Isabell Quagliano-Lo Coco1,3, Stefan Stein1, Alexander Metz4, Joachim Koch1, Jörn Lausen1, Uwe Platzbecker5, Hind Medyouf1, Holger Gohlke4, Michael Heuser2, Matthias Eder2, Manuel Grez6, Michaela Scherr2, Christian Wichmann1,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28154087      PMCID： PMC5685283          DOI： 10.3324/haematol.2016.161570

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Structure of the Bcr-Abl oncoprotein oligomerization domain.

Authors:  Xun Zhao; Saghi Ghaffari; Harvey Lodish; Vladimir N Malashkevich; Peter S Kim
Journal:  Nat Struct Biol       Date:  2002-02

2.  The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.

Authors:  Yizhou Liu; Matthew D Cheney; Justin J Gaudet; Maksymilian Chruszcz; Stephen M Lukasik; Daisuke Sugiyama; Jeff Lary; James Cole; Zbyszek Dauter; Wladek Minor; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2006-04       Impact factor: 31.743

3.  Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.

Authors:  Christian Wichmann; Yvonne Becker; Linping Chen-Wichmann; Vitali Vogel; Anna Vojtkova; Julia Herglotz; Sandra Moore; Joachim Koch; Jörn Lausen; Werner Mäntele; Holger Gohlke; Manuel Grez
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

4.  Oligomerization of ETO is obligatory for corepressor interaction.

Authors:  J Zhang; B A Hug; E Y Huang; C W Chen; V Gelmetti; M Maccarana; S Minucci; P G Pelicci; M A Lazar
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

5.  Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.

Authors:  Christian Wichmann; Linping Chen; Markus Heinrich; Daniela Baus; Edith Pfitzner; Martin Zörnig; Oliver G Ottmann; Manuel Grez
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

6.  From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules.

Authors:  Tamer S Kaoud; Chunli Yan; Shreya Mitra; Chun-Chia Tseng; Jiney Jose; Juliana M Taliaferro; Maidina Tuohetahuntila; Ashwini Devkota; Rachel Sammons; Jihyun Park; Heekwang Park; Yue Shi; Jiyong Hong; Pengyu Ren; Kevin N Dalby
Journal:  ACS Med Chem Lett       Date:  2012-08-06       Impact factor: 4.345

7.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.

Authors:  A B Raitano; J R Halpern; T M Hambuch; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.

Authors:  G S Burgess; E A Williamson; L D Cripe; S Litz-Jackson; J A Bhatt; K Stanley; M J Stewart; A S Kraft; H Nakshatri; H S Boswell
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

9.  AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.

Authors:  Alessandro Gardini; Matteo Cesaroni; Lucilla Luzi; Akiko J Okumura; Joseph R Biggs; Simone P Minardi; Elisa Venturini; Dong-Er Zhang; Pier Giuseppe Pelicci; Myriam Alcalay
Journal:  PLoS Genet       Date:  2008-11-28       Impact factor: 5.917

10.  A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.

Authors:  Xiao-Jian Sun; Zhanxin Wang; Lan Wang; Yanwen Jiang; Nils Kost; T David Soong; Wei-Yi Chen; Zhanyun Tang; Tomoyoshi Nakadai; Olivier Elemento; Wolfgang Fischle; Ari Melnick; Dinshaw J Patel; Stephen D Nimer; Robert G Roeder
Journal:  Nature       Date:  2013-06-30       Impact factor: 49.962
View more
  4 in total

Review 1.  An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.

Authors:  Sayer Al-Harbi; Mahmoud Aljurf; Mohamad Mohty; Fahad Almohareb; Syed Osman Ali Ahmed
Journal:  Blood Adv       Date:  2020-01-14

Review 2.  Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention.

Authors:  Thomas Mercher; Juerg Schwaller
Journal:  Front Pediatr       Date:  2019-10-15       Impact factor: 3.418

3.  Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.

Authors:  Hélène Jakobczyk; Lydie Debaize; Benoit Soubise; Stéphane Avner; Jérémie Rouger-Gaudichon; Séverine Commet; Yan Jiang; Aurélien A Sérandour; Anne-Gaëlle Rio; Jason S Carroll; Christian Wichmann; Michael Lie-A-Ling; Georges Lacaud; Laurent Corcos; Gilles Salbert; Marie-Dominique Galibert; Virginie Gandemer; Marie-Bérengère Troadec
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

4.  Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.

Authors:  Mohanraj Gopalswamy; Tobias Kroeger; David Bickel; Benedikt Frieg; Shahina Akter; Stephan Schott-Verdugo; Aldino Viegas; Thomas Pauly; Manuela Mayer; Julia Przibilla; Jens Reiners; Luitgard Nagel-Steger; Sander H J Smits; Georg Groth; Manuel Etzkorn; Holger Gohlke
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.